You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

CORRECTION article

Front. Endocrinol., 14 March 2022

Sec. Bone Research

Volume 13 - 2022 | https://doi.org/10.3389/fendo.2022.877512

Corrigendum: When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis

  • 1. Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, RI, United States

  • 2. Division of Endocrinology, Diabetes and Bone Diseases, Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany

  • 3. Rheumatic Disease Unit, Western General Hospital, National Health Service (NHS) Lothian, Edinburgh, United Kingdom

  • 4. Rheumatology and Bone Disease Unit, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom

  • 5. Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology [Eidgenössische Technische Hochschule (ETH)] Zurich, Zurich, Switzerland

  • 6. Center for Bone Quality, Division of Endocrinology, Department of Internal Medicine, Leiden University Medical Center, Leiden, Netherlands

Article metrics

View details

1

Citations

1,3k

Views

782

Downloads

In the article as published originally, Elizabeth M. Winter was erroneously presented as the corresponding author instead of Ulrike Baschant.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

glucocorticoid-induced osteoporosis, glucocorticoids, bone fractures, bone density, anti-resorptive treatment, bone density conservation agents, bisphosphonates, teriparatide

Citation

Hayes KN, Baschant U, Hauser B, Burden AM and Winter EM (2022) Corrigendum: When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis. Front. Endocrinol. 13:877512. doi: 10.3389/fendo.2022.877512

Received

16 February 2022

Accepted

23 February 2022

Published

14 March 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2022

Updates

Copyright

*Correspondence: Ulrike Baschant,

This article was submitted to Bone Research, a section of the journal Frontiers in Endocrinology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics